Profil新闻

我们的专家

Lars Bochmann 博士

市场与业务发展执行总监

二月 23, 2023

IDF School of Diabetes: Biosimilar Insulins - Complimentary online course

The IDF School of Diabetes offers a complimentary online course about Biosimilar Insulins, which is co-authored by Profil's Co-Founder and Lead Scientist Dr. Tim Heise. You can also find Profil's

二月 14, 2023

CTR 536/2014: CTIS - the single entry point for submitting clinical trials in the EU (Part 2)

In January 31st, the Clinical Trials Information System (CTIS) became the single entry point for submitting clinical trials in the European Union. Exactly one year before the one-year transition

十二月 22, 2022

CTR 536/2014: Where do we come from and where do we go? (Part I)

Chronological Milestones of the CTR The ‘Clinical Trials Regulation’ (CTR) came into force on 27 May 2014 on condition that there was an EU-wide portal prepared, audited and found to be functional

十二月 20, 2022

Profil World - The clinical diabetes research newsletter - Dec 2022

Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. Profil

十二月 2, 2022

Recent Profil Publications on Biosimilar Insulins

PubMed Central, the free full-text archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health’s National Library of Medicine (NIH/NLM) lists 163 publications

十一月 8, 2022

Free Live Online Seminar: Profil - the leading CRO for metabolic research

We are happy to announce that our successful series of scientific online seminars continues. On December 07th, 2022 at 6 PM CET we will air our next complimentary live online seminar. The session is

十一月 2, 2022

Insulin Infusion System Failure – What’s the matter with the infusion sets?

For patients with type 1 diabetes, continuous subcutaneous insulin infusion (CSII) is a common therapy and represents a concept that, when compared to therapy with multiple daily injections, is

九月 29, 2022

SURMOUNT-1 demonstrates substantial weight loss with Tirzepatide

Aim of the study SURMOUNT-1 [1] evaluated the efficacy and safety of tirzepatide in adults with obesity or overweight without diabetes. Gewichtsverlust / Diäterfolg dank Pillen – Tabletten, Kapseln

九月 28, 2022

Profil World - The clinical diabetes research newsletter - Sep 2022

Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. On-demand